Cost-effectiveness analysis of a quantitative immunochemical test for colorectal cancer screening.
暂无分享,去创建一个
J. Habbema | E. Kuipers | M. van Ballegooijen | M. van Leerdam | E. Dekker | I. Lansdorp-Vogelaar | J. Wilschut | L. Hol | J. Jansen | M. V. van Leerdam | J. Habbema | Ernst J. Kuipers | J. D. F. Habbema | Monique E. Van leerdam | Jan B. Jansen
[1] J. Habbema,et al. Screening for colorectal cancer: random comparison of guaiac and immunochemical faecal occult blood testing at different cut-off levels , 2009, British Journal of Cancer.
[2] N Urban,et al. Quality of life in survivors of colorectal carcinoma , 2000, Cancer.
[3] C. Mulder,et al. Dutch endoscopic capacity in the era of colorectal cancer screening. , 2006, The Netherlands journal of medicine.
[4] J. Habbema,et al. Effect of rising chemotherapy costs on the cost savings of colorectal cancer screening. , 2009, Journal of the National Cancer Institute.
[5] T. Church,et al. Colorectal cancer mortality: effectiveness of biennial screening for fecal occult blood. , 1999, Journal of the National Cancer Institute.
[6] S. Moss,et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer , 1989, The Lancet.
[7] J. Habbema,et al. Screening for colorectal cancer: randomised trial comparing guaiac-based and immunochemical faecal occult blood testing and flexible sigmoidoscopy , 2009, Gut.
[8] G. Miccinesi,et al. Basic variables at different positivity thresholds of a quantitative immunochemical test for faecal occult blood , 2002, Journal of medical screening.
[9] L M Schuman,et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. , 1993, The New England journal of medicine.
[10] F. Nagengast,et al. [Revised CBO guideline 'Follow-up after polypectomy']. , 2001, Nederlands tijdschrift voor geneeskunde.
[11] J. Habbema,et al. The impact of healthcare costs in the last year of life and in all life years gained on the cost-effectiveness of cancer screening , 2009, British Journal of Cancer.
[12] R. Dittus,et al. Utility valuations for outcome states of colorectal cancer , 1999, American Journal of Gastroenterology.
[13] Rob Boer,et al. The MISCAN-COLON Simulation Model for the Evaluation of Colorectal Cancer Screening , 1999, Comput. Biomed. Res..
[14] P. Maisonneuve,et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps. , 2008, Gastroenterology.
[15] M. Weinstein,et al. Guidelines for Pharmacoeconomic Studies , 1997, PharmacoEconomics.
[16] T. Okubo,et al. Estimation of the Optimal Cut Off Point in a New Immunological Faecal Occult Blood Test in a Corporate Colorectal Cancer Screening Programme , 1996, Journal of medical screening.
[17] J. Habbema,et al. A novel hypothesis on the sensitivity of the fecal occult blood test , 2009, Cancer.
[18] Ann G Zauber,et al. National Polyp Study data: Evidence for regression of adenomas , 2004, International journal of cancer.
[19] M C Weinstein,et al. Guidelines for pharmacoeconomic studies. Recommendations from the panel on cost effectiveness in health and medicine. Panel on cost Effectiveness in Health and Medicine. , 1997, PharmacoEconomics.
[20] P. Colquhoun,et al. High compliance rates observed for follow up colonoscopy post polypectomy are achievable outside of clinical trials: efficacy of polypectomy is not reduced by low compliance for follow up , 2004, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.
[21] M. Zorzi,et al. Screening for colorectal cancer in Italy: 2005 survey. , 2007, Epidemiologia e prevenzione.
[22] A. Adrain,et al. A comparison of fecal occult-blood tests for colorectal-cancer screening. , 1996, The New England journal of medicine.
[23] P. Bossuyt,et al. Polyp Miss Rate Determined by Tandem Colonoscopy: A Systematic Review , 2006, The American Journal of Gastroenterology.
[24] J. Coebergh,et al. Trends in colorectal cancer in the south of the Netherlands 1975–2007: Rectal cancer survival levels with colon cancer survival , 2010, Acta oncologica.
[25] S. Moss,et al. The UK colorectal cancer screening pilot: results of the second round of screening in England , 2007, British Journal of Cancer.
[26] Deborah Schrag,et al. How much can current interventions reduce colorectal cancer mortality in the U.S.? , 2006, Cancer.
[27] B. Levin,et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. , 2008, Gastroenterology.
[28] J. Habbema,et al. S1145 Costs of Guaiac Versus Immunochemical Fecal Occult Blood Testing Within a Randomized Population-Based Colorectal Cancer Screening Trial , 2010 .
[29] Michael Pignone,et al. Cost-effectiveness analyses of colorectal cancer screening: a systematic review for the U.S. Preventive Services Task Force. , 2002, Annals of internal medicine.
[30] A. Verbeek,et al. Cutoff value determines the performance of a semi-quantitative immunochemical faecal occult blood test in a colorectal cancer screening programme , 2009, British Journal of Cancer.
[31] Julietta Patnick,et al. Colorectal cancer screening: A comparison of 35 initiatives in 17 countries , 2008, International journal of cancer.
[32] T. Chen,et al. Cost-effectiveness analysis for determining optimal cut-off of immunochemical faecal occult blood test for population-based colorectal cancer screening (KCIS 16) , 2007, Journal of medical screening.
[33] J. Olsen,et al. Randomised study of screening for colorectal cancer with faecal-occult-blood test , 1996, The Lancet.
[34] A. Verbeek,et al. Comparison of Guaiac and Immunochemical Fecal Occult Blood ests for Colorectal Cancer in a Screening Population , 2022 .
[35] Angela Mariotto,et al. Cost of care for elderly cancer patients in the United States. , 2008, Journal of the National Cancer Institute.
[36] M. Gold,et al. Panel on cost-effectiveness in health and medicine. , 1996, Medical care.